Ken Griffin Entrada Therapeutics, Inc. Put Options Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
Put Options
1 transactions
Others Institutions Holding TRDA
# of Institutions
101Shares Held
28.1MCall Options Held
34.5KPut Options Held
16.4K-
Baker Bros. Advisors LP New York, NY4.87MShares$94.3 Million0.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$85.7 Million48.7% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$85.4 Million28.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.05MShares$59.1 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.71MShares$33.2 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $608M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...